(Q34380751)

1 August 2017

title

Off-label use of recombinant factor VIIa in patients following bone marrow transplantation (English)

1 reference

1 August 2017

1 reference

J Blatt

1

1 reference

1 August 2017

S H Gold

2

1 reference

1 August 2017

J M Wiley

3

1 reference

1 August 2017

P E Monahan

4

1 reference

1 August 2017

H C Cooper

5

1 reference

1 August 2017

D Harvey

6

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Bone Marrow Transplantation

1 August 2017

published in

1 reference

1 August 2017

volume

28

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

405-407

1 reference

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703157

Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703157

Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703157

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703157

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1703157

1 reference

Dimensions Publication ID

1 August 2017

1010406626

0 references

1 reference